MyTherakos | Therakos

Clinicians looking at medical results on a tablet

Your account provides access to Webinars and if you are a customer you can also access system documents, events and e-learning

Register today without any obligation or fees.

For over 30 years, we have played a pioneering role in advancing the science of immunotherapy delivered through ECP. We continue to invest in the highest standards of medical education, while seeking to refine our technologies, and remaining dedicated to furthering advances in ECP Immunomodulation.

By registering with MyTherakos, you can take advantage of our event calendar, keep up to date with upcoming webinars and watch those you missed on demand.

If you have a CELLEX^TM System, you will also have exclusive access to the E-Learning platform and a dashboard where you can see the status of your orders, operator manuals, technical bulletins and much more.

Registration to MyTherakos is for healthcare professionals only and is not intended for use in the US and Canada.

Your MyTherakos account gives you access to:

Live Webinars

Live and on-demand webinars, from experienced key opinion leaders. Register for upcoming webinars and quickly review webinars you've already attended.

Member Events

We're more than webinars. The Therakos Institute host symposia, centres of excellence, meet and ask the expert sessions. By creating your MyTHERAKOS account, you can access everything easily.

Exclusive Content

We're continually updating content available within MyTHERAKOS and content from the Therakos Institute. Available to any HCP looking to learn more about ECP.

If you have a CELLEX^TM Photopheresis System in your healthcare facility, you'll also see:

Management Dashboard

Handle everything around your system orders in one simple place including service requests and invoices.

E-learning - Operator Resources

Guidance and materials you need to operate your CELLEX^TM System.

Resource Library

Our operators resources include reference guides, technical bulletins, training materials and user manuals.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.